Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Dermatol Ther. 2022 Oct;35(10):e15736. doi: 10.1111/dth.15736. Epub 2022 Aug 8.
Dermatofibrosarcoma protuberans (DFSP) is a fibrohistiocytic tumor characterized by a high risk of local recurrence but a low risk of metastasis. A small subpopulation of DFSP undergoes fibrosarcomatous (FS) change, and approximately 15%-57% of cases of DFSP with FS change metastasizes, leading to a poor prognosis. In this report, a case of metastatic FS-DFSP that was successfully treated with imatinib mesylate in which the IHC staining pattern of recurrent DFSP was quantitatively analyzed in primary and metastatic DFSP areas, is described. Importantly, the recurrent area was composed of two IHC staining patterns (CD34 PD-L1 Ki67 , and CD34 PD-L1 Ki67 pattern), while the metastatic area showed a clonal pattern (CD34 PD-L1 Ki67 ) in the present case. In this report, we described a case of metastatic fibrosarcomatous DFSP successfully treated with imatinib mesylate. This case suggests a subpopulation of DFSP with a favorable metastatic pattern.
隆突性皮肤纤维肉瘤(DFSP)是一种纤维组织细胞性肿瘤,具有较高的局部复发风险,但转移风险较低。DFSP 中有一小部分会发生纤维肉瘤样(FS)改变,大约 15%-57%的伴有 FS 改变的 DFSP 会发生转移,导致预后不良。在本报告中,描述了一例成功接受甲磺酸伊马替尼治疗的转移性 FS-DFSP 病例,该病例对原发性和转移性 DFSP 区域的复发性 DFSP 的 IHC 染色模式进行了定量分析。重要的是,在本病例中,复发性区域包含两种 IHC 染色模式(CD34+PD-L1+Ki67+ 和 CD34+PD-L1+Ki67-),而转移性区域显示出克隆性模式(CD34+PD-L1+Ki67+)。在本报告中,我们描述了一例成功接受甲磺酸伊马替尼治疗的转移性纤维肉瘤样 DFSP 病例。该病例提示 DFSP 存在具有良好转移模式的亚群。